ADAC Medical Systems, thenewly created equipment division of ADAC Laboratories, will displayVantage, its simultaneous transmission-emission attenuation correctiontechnique for the Vertex adjustable dual-head gamma camera (SCAN6/1/94). The technique is
ADAC Medical Systems, thenewly created equipment division of ADAC Laboratories, will displayVantage, its simultaneous transmission-emission attenuation correctiontechnique for the Vertex adjustable dual-head gamma camera (SCAN6/1/94). The technique is useful in eliminating artifacts createdduring nuclear cardiology procedures. ADAC has submitted a 510(k)application with the Food and Drug Administration for the techniqueand expects to have marketing clearance by December.
ADAC, of Milpitas, CA, will emphasize the throughput advantagesof using Vantage with the gamma camera detectors in the 90ºconfiguration. This offers higher throughput compared to similartechniques used on triple-head cameras, according to Ian Farmer,vice president of nuclear medicine marketing. Picker, the onlyvendor with a simultaneous attenuation correction technique onthe market, uses the technology on its triple-head Prism 3000camera (SCAN 6/1/94).
ADAC will also display 511-KeV collimators for fluorodeoxyglucose(FDG) imaging with Vertex. ADAC expects the technique to showutility in oncology imaging, Farmer said.
On the radiology information systems side, ADAC HealthcareInformation Systems will highlight its QuadRIS product, introducedearlier this year. ADAC will also show its progress in developingan information system for mammography facilities.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.